While Vertex is laser-focused on an upcoming FDA decision for povetacicept in immunoglobulin A nephropathy, the APOL1 inhibitor inaxaplin has demonstrated potential “best-in-class” data in a different ...
With sales of the oral GLP-1 medicine rising quickly, executives reassured investors that Novo has secured production capacity to support continued growth.
With a trillion-dollar market cap and a wildly successful GLP-1 portfolio, Eli Lilly isn’t resting on its laurels. At the ...
With more than 25 companies debuting on the public markets, 2026 has recorded the highest number of biotech IPOs since 2021. Now, four companies—including Iambic Therapeutics and ADARx Pharmaceuticals ...
The mid-stage readout is one link in a chain of catalysts that analysts were watching for this year from Roche’s metabolic pipeline, which features assets from the $2.7 billion acquisition of Carmot ...
As Big Pharma adds AI technology to bolster drug development, a cadre of new, upstart biotechs are pushing drug discovery to ...
HOUSTON and SINGAPORE, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Respiree, a health tech company developing artificial intelligence ...
$12.5 million in support to build talent pipeline, workforce training center with San Jacinto College ...
"We are thrilled to welcome Rajiv De Silva to our Board of Directors," said Craig Mull, Interim Chief Executive Officer of ...
Aviva Bio is a biotechnology company unlocking the potential of hormone-based medicine through novel drug design and evidence ...
The webcast presentation will take place at 10:15 a.m. ET on Tuesday, September 29, 2026. The webcast can be accessed by ...
Rutika Mehta, MD, MPH, a nationally recognized gastrointestinal (GI) medical oncologist, has joined NYU Langone Health's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results